香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （ 於中華人民共和國註冊成立的股份有限公司 ） （股份代號：1666） 公告 董事變更 董事會謹此宣佈，於二零二六年一月十三日，李兆彬先生由於工作變動申請辭 任獨立非執行董事、董事會審核委員會主席、董事會薪酬委員會委員及董事會 戰略與規劃委員會委員。李兆彬先生之辭任將自股東於本公司適時召開的股東 會上選出新任獨立非執行董事起生效。 於二零二六年一月十三日，董事會建議委任蕭耀熙先生為獨立非執行董事。根 據本公司公司章程，該建议委任須待股東於股東會上批准後方可落實。 載有有關上述議案詳細資料的本公司通函將適時寄發予股東。 李先生確認其與董事會並無意見分歧，亦無任何與彼辭任有關事宜須敦請香港聯合交易 所有限公司（「香港聯交所」）及股東垂注。 於二零二六年一月十三日，北京同仁堂科技發展股份有限公司（「本公司」）董事（「董 事」）會（「董事會」）接到李兆彬先生（「李先生」）的辭任函，告知董事會李先生 由於工作變動 ...

Core Insights - The event "Entering Tongrentang, Exploring Traditional Chinese Medicine Culture" marks the launch of the "Double Thousand Stores" initiative aimed at reshaping the retail ecosystem of traditional Chinese medicine [1][3] Group 1: Initiative Overview - The "Double Thousand Stores" project, initiated in July 2025, focuses on transforming partner stores from traditional pharmaceutical sales to comprehensive health services, emphasizing "product strength, service strength, and marketing strength" [3] - The initiative aims to empower terminal upgrades through systematic innovation, injecting new development momentum into the century-old brand [1] Group 2: Supply Chain and Digital Transformation - The company implements a resource allocation strategy to prioritize the stable supply and quality control of 29 key product specifications, reinforcing the product foundation for terminal services [6] - One of the highlights of the "Double Thousand Stores" initiative is the introduction of AI-driven health assessment and diagnostic tools, simulating traditional Chinese medicine practices to provide personalized health management solutions [8][9] Group 3: Marketing and Customer Engagement - The company is developing a diverse and replicable event system, including seasonal health festivals and cultural experience days, to enhance customer engagement and promote the principles of scientific health management [11] - These activities aim to create a sustainable consumption loop, fostering customer loyalty and integrating traditional Chinese medicine culture into daily life [11] Group 4: Future Directions - The successful launch of the initiative signifies a transition from top-level design to regional implementation, with plans to collaborate with more quality terminals to share brand resources and build service capabilities [13] - The company aims to write a new chapter in health services, making the wisdom of the century-old brand accessible to a wider audience in the context of revitalizing traditional Chinese medicine [13]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京同仁堂科技發展股份有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 652,080,000 RMB | | 1 | RMB | | 652,080,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 652,080,000 RMB | | 1 | RMB | | 652,080,000 | | 2. 股份分類 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生 或因依賴該等內容而引致之任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1666） 持續關連交易 續訂物業租賃框架協議 董事會謹此宣佈，由於本公司與集團公司訂立之物業租賃框架協議將於二零二五年十 二月三十一日到期，故訂約雙方於二零二五年十二月三十日續訂該協議，協議期限自 二零二六年一月一日起至二零二八年十二月三十一日止，為期三年，並訂立上述協議 項下截至二零二八年十二月三十一日止三個年度擬進行之持續關連交易年度上限。 集团公司乃本公司之最终控股股东，故根据香港上市规则为本公司之關連人士。因此， 根据香港上市规则第14A章，此次續訂之物業租賃框架協議项下拟进行之交易构成本公 司之持续關連交易。 根據國際財務報告準則第16 號，本集團如以承租人身份訂立租賃交易，應在合併財務 報表中確認使用權資產。本集團以承租人身份訂立的續訂之物業租賃框架協議項下租賃 交易將按香港上市規則第14.04(1)(a) 條規定被視為資產收購。 由於 ...

同仁堂（600085）科技(01666)公布，自2025年12月30日起，杜欣女士获委任为公司第九届董事会的非 执行董事。陈飞先生辞任非执行董事亦于同日起生效。 ...

（於中華人民共和國註冊成立的股份有限公司） （股份代號：1666） 董事名單與其角色及職能 北京同仁堂科技發展股份有限公司 (「 本公司 」)之董事會 (「董事會 」 )成員 載列如下： 執行董事： 張毅（董事長） 張春友（總經理） 溫凱婷 非 執 行董事 ： 杜欣 馮莉 獨立非執行董事： 陳清霞 詹原競 李兆彬 職工董事： 朱東生 1 本公司 設有 四 個董事會委員會，其成員如下： 審核委員會 ： 李兆彬（委員會主席） 陳清霞 詹原競 提名委員會 ： 張春友 陳清霞 詹原競 李兆彬 中國，北京 張毅（委員會主席） 陳清霞 詹原競 薪酬委員會 ： 詹原競（委員會主席） 陳清霞 李兆彬 戰略與規劃委員會： 張毅（委員會主席） 二零二 五年 十 二月 三十 日 2 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 北京同仁堂科技發展股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 欣然宣佈，本公司已於二零二五年十二月三十日（星期二）上午九時三十分假座中華人 民共和國（「中國」）北京市豐台區南三環中路20號舉行股東特別大會（「股東特別大 會」）。本公司日期為二零二五年十二月一日之股東特別大會通告內所載之所有決議案 均獲正式通過。 1 於股東特別大會提呈決議案之投票結果 於股東特別大會上，本公司日期為二零二五年十二月一日之股東特別大會通告所載之決 議案均以投票方式表決。 有關於股東特別大會上所提呈決議案之投票結果如下： | 投票數目（股）及 | | | | 投票股份 | | --- | --- | --- | --- | --- | | 佔總票數百分比 | 普通決議案 | | | 總數 | | 贊成 | | | 反對 | | | 1 | 動議批准及確認本公司與中國北京同仁堂（集團） | | | | | 有限 ...

Core Viewpoint - The recent incident involving Tongrentang's "fake krill oil" has highlighted issues related to the non-compliance of contract manufacturing practices in the consumer industry, prompting the State Administration for Market Regulation to announce the upcoming release of the "Food Contract Manufacturing Supervision and Management Measures" [1][2] Group 1: Regulatory Developments - The State Administration for Market Regulation will soon publish the "Food Contract Manufacturing Supervision and Management Measures," which will include oversight of trademark licensing, franchising, raw material processing, and custom production in food contract manufacturing [1] - The new regulations will clarify the food quality and safety responsibilities of both parties involved in contract manufacturing and improve the relevant regulatory system requirements [1] Group 2: Industry Impact - The "fake krill oil" incident is expected to accelerate the implementation of the aforementioned regulatory measures [2]

Group 1 - The market regulatory authority has responded to the "Antarctic krill oil" incident, highlighting issues related to non-compliance in the entrusted production and processing behaviors of companies [1] - Some companies focus solely on sales profits without ensuring product quality, allowing entrusted manufacturers to produce substandard products [1] - A new "Food Entrusted Production Supervision Management Measures" will be released, which will include supervision of trademark licensing, franchising, and custom production, clarifying the food safety responsibilities of both parties involved [1] Group 2 - The market regulatory authority will guide local departments to strengthen supervision over entrusted production behaviors, such as those seen with Tongrentang's private label processing [1] - A special inspection will be organized to increase the scrutiny of products like krill oil and fish oil, with a focus on cracking down on illegal activities [1] - Tongrentang Group has issued an apology after being implicated in a scandal where the detected content was reported as zero [2]

Core Viewpoint - The article discusses the brand integrity issues faced by Beijing Tongrentang, a historic Chinese medicine brand, due to its extensive licensing and outsourcing practices, which have led to product quality concerns and consumer confusion regarding authenticity [2][5][12]. Group 1: Brand Integrity and Licensing Issues - Beijing Tongrentang has faced backlash after a product, "99% High Purity Antarctic Krill Oil," was found to have no phospholipid content, highlighting the risks associated with its brand licensing strategy [2][3]. - The company has a complex network of over 400 subsidiaries, leading to confusion among consumers about which products are genuinely from the original brand [9]. - The brand's licensing practices have resulted in a proliferation of products under the Tongrentang name, often produced by third-party manufacturers, which has diluted the brand's reputation [5][9]. Group 2: Financial Performance and Market Strategy - Beijing Tongrentang's net profit for 2024 is projected to be 1.526 billion yuan, a decline of 8.54% year-on-year, marking the first negative growth in five years [13]. - The company has attempted to modernize and attract younger consumers through new retail initiatives, but these efforts coexist with traditional practices that may undermine brand trust [12][13]. - The brand's expansion into direct sales of health products has raised concerns about the potential risks associated with this business model, which is often viewed negatively in China [12].